Silver Book reference

Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?

9 Matching Facts

Search matching Facts:
No results to display
    • Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of…  
    • The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately…  
    • From 1970-2000, gains in longevity were greatest for people between the ages of 40 and 60, and greater for men than women, in large part because of advances in the…  
    • Since 1970, reduced mortality from heart disease has increased the value of life by about $1.5 trillion per year. The value of improvements in health care over the 20th century…  
    • From 1970-2000, increased longevity added approximately $3.2 trillion per year to national wealth, the equivalent of half of the average annual gross domestic product over the period. Half of these…  
    • As the prevalence and impact of Alzheimer’s disease grows, so does the cost to the nation. The direct and indirect cost of Alzheimer’s and other dementias amount to more than…  
    • By mid-century, the number of people with Alzheimer’s disease is expected to grow to as many as 16 million, which is more than the current total population of New York…  
    • Combining gains in health-related knowledge of Alzheimer’s disease and its application for both genders, reductions in mortality between 1970 and 2000 yielded additional life-years with an end of century value…  
    • It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall…